Please find enclosed the disclosure under Regulation 30 of SEBI LODR Regulations regarding Earnings Presentation for Q1 FY 27

Press Release - Q1 FY27 - Total Operating Income ₹942 Mn +31.2% y-y, down 10.5% q-q - EBITDA ₹34 Mn, margin 3.7% vs 7.9% Q1 FY26; margin decline due to higher utility and employee costs - PAT loss ₹40 Mn vs loss ₹19 Mn Q1 FY26; higher depreciation and finance costs from scale-up investments - Pharma business 72% revenue, Nutra 28%; Pharma +20%, Nutra +71% y-y - Innovative Products revenue tripled to ₹138 Mn, 15% of sales - Export revenue 84%, grew 31.7% y-y; domestic +24% y-y - R&D spend ₹82 Mn (8.7% of sales) sustaining innovation pipeline - EU-GMP CAPA remediation progressing; alternate manufacturing and audits ongoing